Table 5. Association between first FSH test and time from ADT to all-cause mortality.
| FSH measures | Univariable | Multivariable* | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | ||
| FSH—continuous | 1.01 | 1.01–1.02 | <0.001 | 1.01 | 0.99–1.01 | 0.10 | |
| FSH—log continuous | 1.23 | 1.11–1.37 | <0.001 | 1.04 | 0.93–1.16 | 0.47 | |
| FSH—categorical | |||||||
| Low/normal (≤8 UI/mL) | Ref. | – | – | Ref. | – | – | |
| High (>8 UI/mL) | 1.22 | 1.05–1.41 | 0.008 | 1.03 | 0.88–1.20 | 0.70 | |
*, adjusted for age, year, race, BMI, Charlson Comorbidity Index, primary treatment, biopsy grade group, PSA, time from FSH to ADT, and chemotherapy (time-dependent). FSH, follicle-stimulating hormone; ADT, androgen deprivation therapy; HR, hazard ratio; CI, confidence interval; Ref., reference; BMI, body mass index; PSA, prostate-specific antigen.